Scarica l'app Stockscreener
1.56
1.30%
0.02
Dopo l'orario di chiusura:
1.53
-0.03
-1.92%
Precedente Chiudi:
$1.54
Aprire:
$1.55
Volume 24 ore:
60,241
Relative Volume:
0.22
Capitalizzazione di mercato:
$66.91M
Reddito:
$51.13M
Utile/perdita netta:
$-93.80M
Rapporto P/E:
-0.6996
EPS:
-2.23
Flusso di cassa netto:
$-129.10M
1 W Prestazione:
+1.30%
1M Prestazione:
+4.00%
6M Prestazione:
+35.65%
1 anno Prestazione:
-49.02%
Intervallo 1D:
$1.5346
$1.56
Intervallo di 1 settimana:
$1.48
$1.56
Portata 52W:
$0.89
$4.0695
Repare Therapeutics Inc Stock (RPTX) Company Profile
Nome
Repare Therapeutics Inc
Settore
Industria
Telefono
(857) 412-7018
Indirizzo
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Confronta RPTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.56 | 66.05M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-06-09 | Aggiornamento | Stifel | Hold → Buy |
| 2023-02-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | Iniziato | CapitalOne | Overweight |
| 2022-04-12 | Downgrade | Stifel | Buy → Hold |
| 2022-03-17 | Ripresa | Goldman | Buy |
| 2021-09-23 | Iniziato | Stifel | Buy |
| 2021-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-28 | Iniziato | Guggenheim | Buy |
| 2021-03-01 | Iniziato | Berenberg | Buy |
| 2020-10-28 | Iniziato | Northland Capital | Outperform |
| 2020-07-14 | Iniziato | Cowen | Outperform |
| 2020-07-14 | Iniziato | Goldman | Neutral |
| 2020-07-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-14 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Repare Therapeutics Inc Borsa (RPTX) Ultime notizie
Candlestick Reversal Detected on Repare Therapeutics Inc.’s ChartScalable Portfolio Growth Suggestions Released - 선데이타임즈
Is Repare Therapeutics Inc. still worth holding after the dipFree Risk-Adjusted Picks With Exit Strategy - Newser
Using portfolio simulators with Repare Therapeutics Inc. includedSafe Investment Ideas with Growth Upside - Newser
Repare Therapeutics (NASDAQ:RPTX) Posts Earnings Results - MarketBeat
Wall Street Zen Upgrades Repare Therapeutics (NASDAQ:RPTX) to "Hold" - MarketBeat
Is Repare Therapeutics Inc. forming a reversal patternFree Market Surge Signal for Swing Traders - Newser
Backtesting results for Repare Therapeutics Inc. trading strategiesPattern Recognition Based Market Move Prediction - Newser
Is Repare Therapeutics Inc. Stock a Good Fit for Conservative InvestorsSafe Momentum Strategy With Trend Analysis - Newser
Repare Therapeutics Q2 2025 Earnings: EPS Beats Estimates, Revenue Surpasses Expectations - AInvest
Repare Therapeutics Inc (RPTX) Q2 2025 Earnings: EPS of -$0.39 B - GuruFocus
Will Repare Therapeutics Inc. benefit from macro trendsDay Trading Plan with Entry Risk Management - Newser
Analyzing recovery setups for Repare Therapeutics Inc. investorsFree Smart Trend Trading with Weekly Signals - Newser
Repare Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Repare Therapeutics Reports Q2 2025 Results and Strategic Moves - TipRanks
Repare Therapeutics Reports Q2 Earnings: Strategic Moves and Upcoming Data Releases - AInvest
Repare 2025 Q2 Earnings Strong Improvement as Net Loss Narrows 51.8% - AInvest
Repare Therapeutics Cuts Losses And Snags New Licensing Deals - Finimize
Repare Therapeutics Narrows Losses And Seeks New Paths Forward - Finimize
Repare (RPTX) Q2 Loss Narrows 52% - AOL.com
Repare Therapeutics' Strategic Shift and Milestone-Driven Outlook - AInvest
Repare Therapeutics Announces Licensing Deal and Strategic Updates - TipRanks
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Repare Therapeutics reports Q2 EPS (39c) vs. (82c) last year - TipRanks
Repare Therapeutics Inc. SEC 10-Q Report - TradingView
Repare Therapeutics Q2 net loss narrows to $16.7 mln - MarketScreener
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results | RPTX Stock News - GuruFocus
Repare Therapeutics reports Q2 2025 revenue $109.5 mln, cash & marketable securities. - AInvest
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - The Globe and Mail
Predicting Repare Therapeutics Inc. trend using moving averagesChart Scanner for Swing Trade Timing - Newser
Repare Therapeutics Provides Business Update and Reports Second - GuruFocus
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Daily Profit Focused Stock Screener - Newser
Can Repare Therapeutics Inc. hit a new high this monthFree Low Risk Swing Trade Opportunity List - Newser
Quantitative breakdown of Repare Therapeutics Inc. recent movePredicted Market Direction Based on Momentum - Newser
What makes Repare Therapeutics Inc. stock price move sharplyUnlock market-leading stock analysis - Jammu Links News
Should I hold or sell Repare Therapeutics Inc. stock in 2025Maximize gains with proven stock analysis - Jammu Links News
Repare Therapeutics Inc. Stock Analysis and ForecastAchieve rapid wealth accumulation with smart picks - Jammu Links News
How volatile is Repare Therapeutics Inc. stock compared to the marketMaximize portfolio value with smart investment plans - Jammu Links News
When is Repare Therapeutics Inc. stock expected to show significant growthAmplify your gains with low-risk picks - Jammu Links News
Does Repare Therapeutics Inc. stock perform well during market downturnsMaximize returns with data-driven strategies - Jammu Links News
Is Repare Therapeutics Inc. a growth stock or a value stockUnlock your portfolio’s hidden potential - Jammu Links News
How many analysts rate Repare Therapeutics Inc. as a “Buy”Capitalize on momentum stocks before they peak - Jammu Links News
Repare Therapeutics Inc Azioni (RPTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):